Boehringer Ingelheim and South Korean biotech Bridge Biotherapeutics have announced a deal to develop the latter’s drug for idiopathic pulmonary fibrosis (IPF).
Boehringer Ingelheim has filed for a new use for its lung drug nintedanib in the US and Europe, bidding to add the rare disease systemic sclerosis to the existing indication for idiopathic
Idiopathic pulmonary fibrosis (IPF) is a fatal disease that's all the more difficult for patients because of a lack of awareness and investment in supporting people with the condition.